RxDoctor Payments Data

Mel Magboo, MD

Geriatric Medicine · Reno, NVNPI 1114937158

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 6 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Neurocrine Biosciences, Inc. accounts for 63.5% of it on its own, with 4 other manufacturers making up the rest. That places this record below the midpoint for geriatric medicine clinicians in NV, where the typical reported total is $231.

$231in general payments, 2019–2025

Across 6 payments — averaging $38.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$147
  • Otsuka America Pharmaceutical, Inc.$30
  • Lilly USA, LLC$20
  • Aimmune Therapeutics, Inc.$19
  • Exact Sciences$16

What the payments were for

  • Food & beverage$231100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$231 in reported general payments places this provider in the 50th percentile of 36 geriatric medicine providers in Nevada.

See all geriatric medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$481,416
Medicare patients
516
Services billed
4,594

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban732$243,842
XareltoRivaroxaban355$110,536
XifaxanRifaximin25$41,757
JardianceEmpagliflozin87$37,505
Breo ElliptaFluticasone/Vilanterol73$30,208
CreonLipase/Protease/Amylase17$24,035
Incruse ElliptaUmeclidinium Bromide65$23,674
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$21,456
Atorvastatin Calcium1,374$20,380
Divalproex Sodium449$18,187
JanuviaSitagliptin Phosphate42$17,591
FarxigaDapagliflozin Propanediol49$17,240
Potassium Chloride556$16,930
RexultiBrexpiprazole13$16,601
OzempicSemaglutide14$14,270

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$30$16,60113 claims
Lilly USA, LLCTrulicity$20$9,68819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 36 geriatric medicine providers in Nevada.

Other geriatric medicine in Reno

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →